can be processed in less than 4-6 h. Application of Bio-Gel P-10 gel filtration to determine the IGF-I and IGF-II levels in 14 normal and 15 age-matched postmenopausal osteoporotic women revealed that 1) both IGF-I and IGF-II levels were reduced by 30% (P i 0.01) and 20% (P < 0.051, respectively, in osteoporotics;
and 2) both IGF-I and IGF-II levels correlated with bone mineral density in the pooled data from normal and osteoporotic populations even when age was held constant (P < 0.05). (J Clin Endocrinol Metab SO: 637-647, 1995) I NSULIN -like growth factor-I (IGF-I) and IGF-II, previously known as somatomedins, are structurally related to insulin and are the two most abundant polypeptide growth factors that circulate in human plasma. IGF-I and IGF-II are of recognized importance for regulating the proliferation and differentiation in a multitude of cell types, including cells derived from brain, thyroid, liver, muscle, kidney, blood, and bone. Many of these cell types have been shown to produce IGFs in culture, contain high affinity receptors for IGFs, and exhibit biological responses to exogenously added IGFs. Thus, IGFs have been proposed to play a significant role in local regulation, such that the IGFs produced by one cell type can act on the same cell type in an autocrine manner or on a neighboring cell type in a paracrine manner (l-5). IGFs circulate in plasma as large mol wt proteins bound to specific proteins, which are termed IGF-binding proteins (IGFBPs) . Six different IGFBPs (designated IGFBP-1 through have been purified and cloned from a variety of human tissues thus far (6) (7) (8) . Recent studies emphasize a number of important functions for IGFBPs, including 1) prevention of acute metabolic effects of free IGFs, specifically hypoglycemia;
2) increasing the half-life of the IGFs in the circulation;
3) regulation of the bioavailability of IGFs in the local areas; and 4) providing tissue specificity for the local actions of .
The existence of these IGFBPs in serum and other biological fluids, such as conditioned medium, has complicated the application of specific radioligand assays (RIA and RRA) for measurement of IGFs, because IGFBPs can compete with the antibody or receptors for tracer binding (9) (10) (11) (12) (13) (14) Gel filtration chromatography using Sephadex G-75 column in a fast protein liquid chromatography (FPLC)
The FPLC column HR IO/30 (1 X 30 cm) was packed with Sephadex G-75 using 1 mol/L acetic acid containing 0.1 mol/L NaCl as buffer. Serum (0.1 mL) was mixed with 0.4 mL 1.25 mol/L acetic acid containing 0.125 mol/L NaCl and incubated at room temperature for 15 min before its application to the column using a 0.2-mL sample loop. The proteins were eluted at a flow rate of 0.5 mL/min. To determine how much of residual IGFBPs is left after extracting the serum samples with various extraction procedures, two methods were employed. First, untreated and acid-ethanol-, Sep-Pak-, and Sephadex G-75-extracted serum samples were subjected to acid gel filtration using Sephadex G-75 in a FPLC system to separate IGFs from IGFBPs before analysis. Figure 2 shows the elution profile for IGFBPs, IGF-I, and IGF-II obtained during the acid gel filtration of human serum after various extraction procedures compared with the untreated serum sample. IGFBP activity (fractions 9-15) eluted between mol wt markers BSA (67,000) and myoglobin (17,500). There was no detectable IGFBP activity in the region where IGFs eluted (fractions 15-22). Upon comparison of the IGFBP activity profile, it is evident that a significant amount of IGFBP activity is still retained in the serum samples after extraction with acid-ethanol and Sep-Pak, but not after Sephadex G-75 acid gel filtration. Although the acid-ethanol cryoprecipitation method was slightly better than standard acidethanol extraction, a significant amount of IGFBPs remained unextracted even after this procedure (data not shown). Analysis of Sephadex G-75 fractions for IGF-I and IGF-II activity by RIA yielded two peaks of activity for untreated and acid-ethanol-and Sep-Pak-extracted serum samples (Fig. 2) . The high mol wt IGF-I and IGF-II activity peak (fractions 8-14) corresponded with the IGFBP activity peak, suggesting that this peak of IGF-like activity was probably due to IGFBP artifacts. Consistent with this interpretation, preincubation of aliquots of these fractions with excess unlabeled IGF-II or IGF-I (in IGF-I and IGF-II radioligand assays, respectively) abolished the IGF-like activity in the IGF RIAs. The low mol wt IGF activity peak coeluted with ['251]IGF and was not abolished upon preincubation with excess of unlabeled IGF (data not shown). In contrast to acid-ethanol-and Sep-Pak-extracted serum samples, the IGF pool obtained after Sephadex G-75 gel filtration yielded no measurable IGF-like activity in the high mol wt region.
The results obtained with Sephadex G-75 separation of acid-ethanol-and Sep-Pak-separated IGF pools were further confirmed by a second method, in which extracted serum samples were subjected to Western ligand blot analysis for quantification of IGFBPs. Both acid-ethanol and Sep-Pak methods were found to be efficient in removing higher mol wt proteins, but not low mol wt IGFBPs (Fig. 3A) and amount of IGFBPs left unextracted appeared to be different in acid-ethanol-and Sep-Pak-extracted samples. In contrast to acid-ethanol and Sep-Pak procedures, FPLC acid gel filtration using Sephadex G-75 resulted in complete removal of IGFBPs from serum, because no IGFBP bands could be seen even after 2-3 weeks of exposure of nitrocellulose membrane to x-ray film at -70 C (Fig. 3B) . Based on these data, it is obvious that separation of IGFs in human serum samples by Sephadex G-75 gel filtration, but not by the acidethanol or Sep-Pak procedure, is valid for complete removal of IGFBPs from IGFs.
Centrifugal ultrafiltration
We also evaluated the approach of using centrifugal ultrafiltration of human serum under acidic conditions to dissociate and separate IGFs from IGFBPs. As the mol wt of IGF-I and IGF-II [7.5-7.7 kilodaltons (kDa)] are much smaller than those of IGFBPs (25-50 kDa), in our initial studies we used Ultrafree-MC lo-kDa filter units (10 kDa mol wt cut-off membrane; Millipore, Bedford, MA) to separate IGFs from IGFBPs. Ultracentrifugation of 0.05 mL acidified serum (0.010 mL serum diluted with 0.04 mL 1 mol/L acetic acid) containing 10,000 cpm [ iz51]IGF-I, followed by three rinses with 1 mol/L acetic acid revealed that only 25-30% ['251]IGF-I filtered through the lo-kDa mol wt cut-off membrane (data not shown). We next used Ultrafree-MC 30-kDa filter units (30 kDa mol wt cut-off membrane) and 1 mol/L acetic acid, 4 mol/L guanidine HCl, or 50% acetonitrile containing 0.1% TFA as a dissociating agent. It was found that although the recovery of [ 125 11 IGF-I in the filtrate could be improved somewhat by using Ultrafree-MC 30-kDa filter units, 50-60% of the ['251]IGF-I was still retained in the retentate (Table 1) .
Separation
of IGFs from IGFBPs by Bio-Spin P-10 chromatography Because the best separation of IGFs from IGFBPs was achieved by gel filtration under acidic conditions, we investigated the possibility of combining centrifugation and acid gel filtration to find a method that is less tedious and less time consuming than gel filtration alone, so that large number of samples can be processed in a reasonable time frame. For this purpose, we selected Bio-Gel P-10 polyacrylamide gel for the following reasons: 1) Bio-Gel P-10 is resistant to pressure up to 15 psi and, thus, could withstand centrifugational force; 2) Bio-Gel P-10 is resistant to pH 2-10 and, thus, 1 mol/L acetic acid could be used for separation; and 3) the exclusion limit of Bio-Gel P-10 is 20,000 and, thus, all IGFBPs, but not IGFs, could be eluted in the void volume. To determine the usefulness of Bio-Gel P-10 for separation of IGFs and IGFBPs, ]'2'I]IGF-I in 0.05 mL Bio-Spin elution buffer was applied to a Bio-Spin column containing Bio-Gel P-10 and centrifuged for 5 min. The column was subsequently washed twice with 0.05 mL buffer (fractions 2 and 3) and four times with 0.5 mL elution buffer (fractions 4-7). The elution profile for [12"I]IGF-I in the absence or presence of human serum using Bio-Spin P-10 chromatography showed that the void volume fractions (1 and 2) contained less than 5% of the total counts added. More than 95% of the total ['2"I]IGF-I recovered was found in fractions 4-6. In addition, when purified IGF-I was applied to a Bio-Spin P-10 column, no detectable IGF-I was found in column fractions 1 and 2 and that fractions 4 and 5 contained greater than 90% of the total IGF-I recovered. Figure 4 shows the profile for IGFBP, IGF-I, and IGF-II in P-10 column fractions when 0.05 mL acidified serum (0.01 mL serum and 0.04 mL 1.25 mol/L acetic acid containing 0.125 mol/L NaCl) was subjected to Bio-Spin P-10 chromato g raphy. IGFBP activity determined by precipitation of the ['2~I]IGF-I-IGFBP complex with polyethylene glycol was found in fractions 1 and 2, with no detectable IGFBP activity in fractions 3-7. In contrast to IGFBP activity, there were two peaks of IGF-I activity; peak 1 corresponded to the elution position of IGFBPs, and peak 2 corresponded to the elution position of ['2"I]IGF-I. Similarly, there were two peaks of IGF-II activity that corresponded to the elution positions of IGFBPs and ['2sI]IGF-II, respectively. IGF-I and IGF-II activities in peak 1 seemed to be due to IGFBP artifacts, because this activity could be abolished upon preincubation of these fractions with excess IGF-II or IGF-I before radioligand assays (data not shown).
The artifacts produced by IGFBPs appeared to be significantly higher in the IGF-II RIA than in IGF-I RIA, because the IGF-II-like activity in the IGFBP peak was 3-5 times that of actual IGF-II, whereas the IGF-I like activity in IGFBP peak was l-2 times that of actual IGF-I. The absence of any detectable IGFBP activity or IGF activity in fraction 3 suggests that the separation of IGFBPs and IGFs is complete, with no overlap in the elution between IGFs and IGFBPs under the chromatographic conditions used in this study.
Studies to determine whether separation between IGFBI's and IGFs in human serum could be improved by using other types of Bio-Gel revealed that Bio-Gel P-10 was superior to Bio-Gel P-6 or Bio-Gel P-30, which have nominal exclusion limits of 6 and 40 kDa, respectively.
In addition, Sephadex G-50 (nominal mol wt cut-off, 30,000) could not be substituted for Bio-Gel types of for Bio-Spin separation, because Sephadex G-50 beads did not withstand the centrifugational force used in this study for elution of proteins (data not shown).
Pretreatment
of Bio-Gel P-10 with BSA improves the recovery of IGFs
The recovery of purified IGF-I in the absence of serum after Bio-Spin P-10 separation was low (<4070). In addition, it was found that the recovery of IGF-I was significantly increased if the serum samples were applied to Bio-Spin columns that had been used previously for separation of IGFs from IGFBPs in serum. Table 2 shows that the recovery of IGF-I in eight human serum samples after the first run was 40-50% of that in subsequent runs. There was no significant difference between runs 2 and 3. Subsequent studies suggested that a significant amount of IGFs was lost during the first run due to nonspecific binding of IGFs to the Bio-Gel P-10 beads even in the presence of 1 mol/L acetic acid and that this nonspecific binding of IGFs to beads could be eliminated by pretreating the Bio-Gel P-10 beads overnight with serum proteins or BSA. Table 3 shows that more than 50% of the ['251]IGF-I was retained in the column if Bio-Gel P-10 beads were soaked only in 1 mol/L acetic acid before use. However, pretreatment of Bio-Gel P-10 beads with 1% serum proteins or 1% BSA significantly reduced nonspecific binding (<2% of the added ['2"I]IGF-l was retained in the column). Consistent with these data, mean IGF-I values in normal human serum pool using BSA-pretreated and untreated Bio-Gel P-10 were 221 t 5 and 95 + 13 pg/L (mean + SD; n = 5; P < O.OOl), respectively.
In addition, it was found that there was no significant difference in serum IGF-I values after one, two, or three runs if BSA-pretreated Bio-Gel P-10 was used for separation (data not shown).
To determine the recovery of purified IGF-I after Bio-Spin P-10 separation, 0.05 mL 250 pg/L IGF-I in 1 mol/L acetic acid-O.1 mol/L NaCl was applied to the column, and the amount of IGF-I in IGF pool was determined after Bio-Spin separation.
The amount of IGF-I recovered in four different samples was 91 -C 2.5% (mean + SD) of the added IGF-I. Studies on the recovery of exogenously added IGF-I to human serum samples revealed that the recovery ranged between 91-109% for various IGF-I concentrations.
To determine whether the Bio-Spin P-10 separation technique could be applied for separation of IGFs in conditioned medium samples that contained low levels of IGF To determine the intraassay column variation, 1 serum sample was applied to 6 different columns, and the serum IGF-I level was determined after Bio-Spin separation. The intraassay column variation for six columns was less than 6% (245 k 14; range, 224-267 pg/L).
To determine interassay variation, 20 serum samples were subjected to Bio-Spin P-10 chromatography on 2 different days (i.e. 2 separate assays). The IGF pools were dried by Speed-Vat centrifugation to remove acetic acid before IGF-I RIA. Figure 5 shows that the correlation coefficient for IGF values obtained for the 2 runs was 0.913 (P < 0.001). The interassay coefficient of variation between the 2 runs was 11 + 7% (range, O-24%; n = 20). In our subsequent studies, we found that the interassay variation could be improved by avoiding the Speed-Vat centrifugation step and assaying the IGF pool directly after neutralization with Tris base. The interassay coefficient of variation between the 2 runs using the neutralization step rather than Speed-Vat centrifugation was 8 k 5% (range, O-16%; n = 20). (The linear regression between the two extraction methods for IGF-I was r = 0.95 and P < 0.001; for IGF-II, it was r = 0.90 and P < 0.001.) poor correlation for IGF-I (Table 4 ). The r value obtained in this study between acid ethanol extraction and FPLC gel filtration was less than that previously reported (16). The difference in r values between acid-ethanol extraction and size-exclusion chromatography obtained in different laboratories could be explained in part by differences in the affinity of the IGF-I antibodies used. Consistent with this interpretation, we obtained a better correlation between the two extraction protocols for IGF-I than IGF-II determination by using an IGF-I antiserum with a higher affinity than the Twelve human serum samples were subjected to various pretreatments before IGF-I determination by RIA. = P < 0.01. b P < 0.05. "P < 0.02.
IGF-II antiserum for their respective ligands (data not shown).
The efficacy of the Bio-Spin P-10 separation technique for removal of IGFBPs was further determined using Western ligand blot analysis. The IGF pool obtained after Bio-Spin P-10 separation of human serum samples contained no measurable IGFBP bands even after 3 weeks of exposure of nitrocellulose membrane to x-ray film (Fig. 7) . In addition, analysis of Bio-Spin IGF pools for 10 serum samples for the presence of IGFBP-3 by RIA revealed no detectable IGFBP-3 (<5 pg/L in 1:20 diluted extracted serum samples). In contrast, analysis of acid-ethanol-treated samples revealed that approximately 20% of IGFBP-3 remained unextracted after this procedure (908 + 370 pg/L in acid-ethanol extracted serum VS. 4900 + 1200 pg/L in unextracted serum samples; n = 10).
To determine whether the free IGFbPs, if present in excess in serum, would influence the recovery of IGFs, 10 mg/L purified IGFBP-3 and 4 mg/L IGFBP-5 were added to the serum sample before Bio-Gel P-10 separation. Table 5 shows that exogenously added IGFBP-3 or IGFBP-5 had no effect on IGF-I or IGF-II determinations. In addition, no IGF-I or IGF-II-like activity could be detected in the samples containing IGFBP-3 or IGFBP-5 but no serum. These data suggest that Bio-Gel P-10 gel filtration is valid in removing IGFBP artifacts completely, even in samples containing high concentrations IGFBPs.
IGF-I and IGF-II levels in the serum of normal and osteoporotic women IGF-I and IGF-II levels were significantly lower in the osteoporotic women than those in age-matched normal sub- Western ligand blot analysis of fractions obtained during Bio-Spin P-10 separation of human serum samples. Acidified serum samples were subjected to acid gel filtration using Bio-Gel P-10, as described in Materials and Methods.
The fractions were dried, reconstituted in electrophoresis sample buffer, and subjected to ligand blotting using [ 1251]IGF-II as tracer. Lanes l-3 represent serum sample 1, lanes 4-6 represent serum sample 2, lanes 7-9 represent serum sample 3, and lanes lo-12 represent serum sample 4. Lanes 1,4,7, and 10 represent void volume fractions (IGFBP pool); lanes 2,5,8, and 11 represent 0.05 mL rinse 1; lanes 3,6,9, and 12 represent the IGF pool. Data shown here are representative of four experiments. Bone Density (mg/cm3) jects (Table 6 ). Mean IGF-I (140.6 5 43.3 pg/L) and IGF-II (494 t 133 pg/L) levels in the normal group of subjects were decreased by 30% (P < 0.01) and 20% (P < 0.051, respectively, in the osteoporotic group. Both IGF-I (r = 0.50; P < 0.01) and IGF-II (r = 0.47; P < 0.01) correlated positively with bone mineral density (Fig. 8) in the pooled data from the normal and osteoporotic populations. The correlation, however, was not significant in either group if analyzed individually. Although serum IGF-I and IGF-II correlated negatively with age in the pooled data from both the normal and osteoporotic groups (r = -0.34; P < 0.1 and r = -0.37; P < 0.05, respectively), the correlation between serum IGFs and bone mineral density remained significant even when age was held constant (r = 0.44 and 0.39, respectively, for IGF-I and IGF-II US. bone mineral density; P < 0.05). The correlation between IGF-I and IGF-II in these subjects was 0.68 (P < 0.001).
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